GlassScriptPhysician profile
Elizabeth Osborn
NPI 1881828457
$5,828.44
in general payments reported to CMS, 2019-2025
39 companies · $979 in 2025
The $979 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $1,410 · 2021: $724 · 2023: $591 · 2024: $714 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $942.65 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $833.91 | 2019-2025 | |
| Novo Nordisk INC | $534.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $392.32 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $250.55 | 2019-2024 | Veozah |
| Lilly USA, LLC | $205.70 | 2019-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $201.29 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.14 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $178.07 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $167.29 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Exact Sciences Corporation | $159.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $156.54 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.80 | 2019-2023 | Spiriva Respimat, Synjardy, Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.